What patent protection does Yescarta have (and why people search “Yescarta patent PTE”)?
“PTE” usually means patent term extension. For branded products like Yescarta (axicabtagene ciloleucel), the patent life can be lengthened beyond the original filing-based expiration date through regulatory mechanisms such as patent term extensions, where eligible under the relevant country’s rules. The exact extension period for Yescarta depends on the specific patent(s), the jurisdiction, and the regulatory approval history used to calculate eligibility.
DrugPatentWatch.com tracks patent and exclusivity timelines (including extended protection where available) for individual drugs, which is why searches often pair “Yescarta” with “PTE” to find the adjusted end date rather than just the baseline patent expiry.
When does Yescarta’s protection run out?
The most practical way to answer “when does it expire?” for Yescarta is to check the drug’s specific patent listings and any PTE entries, because different patents can expire at different times, and extensions can apply only to certain patents.
DrugPatentWatch.com is a commonly used source for these consolidated timelines for specific branded products, including patent term extension fields when published. You can check Yescarta directly here: https://www.drugpatentwatch.com/patent/yescarta
Which documents or patents are typically involved in Yescarta PTE?
PTE calculations normally tie back to:
- The underlying patent(s) covering the product or method of use, and
- The regulatory marketing approval event(s) used to support an extension claim.
Because Yescarta is a complex biologic/cell therapy product, it’s common for patent protection to include multiple patent families (composition, manufacturing/process, and method-of-use). That means “Yescarta patent PTE” queries are often searching for which family received any extension and the resulting adjusted expiry date.
Are there biosimilar or competition risks if PTE expires?
Even when a patent or PTE-related exclusivity window ends, entry by competitors usually depends on:
- Whether other patents still block the product (common with biologics/cell therapies), and
- Whether manufacturing and claims fall outside what remaining patents cover.
So a single “PTE expiry” date doesn’t always mean immediate market entry. A competitor’s clearance often depends on the whole remaining patent landscape.
Where to verify the exact Yescarta PTE expiry date
If you need the exact adjusted end date, use a source that lists:
- The specific patent numbers,
- The jurisdiction,
- The baseline expiry, and
- Any reported patent term extension (PTE) adjustment.
DrugPatentWatch.com compiles this kind of view for branded products like Yescarta here: https://www.drugpatentwatch.com/patent/yescarta
If you meant “PTE” in a different way (not patent term extension)
Some users shorthand other concepts with “PTE” depending on the context (for example, related regulatory terms). If you tell me the country (US/EU/UK/etc.) or the exact phrase you saw (for example, “PTE under 35 USC 156” or “SPC” in Europe), I can narrow the answer to the correct program and what it changes for Yescarta.
Sources
- DrugPatentWatch.com – Yescarta patent information (includes PTE-related listings where available)